Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 3c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $13.67 million versus the consensus estimate of $11.19 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• J. M. Smucker (SJM) Raises Quarterly Dividend 1.8% to $1.12; 4% Yield
• Citi Upgrades Grupo Aeroportuario del Pacifico SAB de CV (GAPB:MM) (PAC) to Buy